%0 Journal Article %@ 0022-1899 %A Gardner, Annelys Roque %A Ma, Yifei %A Bacchetti, Peter %A Price, Jennifer C %A Kuniholm, Mark H %A French, Audrey L %A Gange, Stephen %A Adimora, Adaora A %A Minkoff, Howard %A Kassaye, Seble %A Ofotokun, Igho %A Rosenberg, William %A Kovacs, Andrea AZ %A Tien, Phyllis C %D 2023 %F discovery:10157002 %I Oxford University Press (OUP) %J Journal of Infectious Diseases %K APRI, ELF, FIB-4, HIV, direct-acting antiviral therapy, enhanced liver fibrosis score, hepatitis C %N 11 %P 1274-1281 %T Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment %U https://discovery.ucl.ac.uk/id/eprint/10157002/ %V 227 %X BACKGROUND: The trajectory of liver fibrosis is not well understood in the contemporary era of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) therapy. METHODS: We assessed the Enhanced Liver Fibrosis (ELF) score, aspartate transaminase-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) in 116 women with HIV/HCV coinfection over a 4-year period. Random-effects linear regression models examined the rate of fibrosis change 1-2 years before starting HCV treatment, within 1 year before starting (peri-HCV treatment), within 1 year after and 1-2 years post-HCV treatment in unadjusted and adjusted models including age, race, and changes from pretreatment of factors that might affect fibrosis (eg, alcohol, integrase strand inhibitor [INSTI] use, waist circumference, CD4 count). RESULTS: INSTI use nearly doubled from pre- to peri-HCV treatment. In unadjusted analysis, there was a 3.3% rate of rise in ELF pre-HCV treatment, 2.2% and 3.6% rate of decline during the peri- and 1-year post-HCV treatment period, respectively, followed by a 0.3% rise. Similar findings were observed for APRI and FIB-4. There was little effect on the estimated fibrosis trajectories after adjustment. CONCLUSIONS: The apparent lack of decline in biomarkers of liver fibrosis beyond 1 year after HCV cure suggests that continued monitoring of liver fibrosis and interventions to mitigate progression in people with HIV after HCV cure remains essential. %Z This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.